Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.

Latest News

Lugano, Switzerland and Berlin, Germany, January 27, 2020 : Helsinn Group (“Helsinn”), a Swiss pharmaceutical group focused on building quality canc...
Menarini Consumer Healthcare  has entered a partnership with  Alibaba , one of the world’s leading technology companies, by opening a  flagship stor...
Menarini Ricerche is progressing with the clinical development of SEL24/MEN1703, and will be presenting the design of the ongoing First In Human clin...
READ ALL NEWS »
Helsinn Grants Exclusive Licensing Rights to Berlin-Chemie Menarini, for ONICIT®/ALOXI® and AKYNZEO® in Russia and CIS region

Helsinn Grants Exclusive Licensing Rights to Berlin-Chemie Menarini, for ONICIT®/ALOXI® and AKYNZEO® in Russia and CIS region

Lugano, Switzerland and Berlin, Germany, January 27, 2020 : Helsinn Group (“Helsinn”), a Swiss pharmaceutical group focused on building quality cancer care products, has granted exclusive licensing rights to commercialize AKYNZEO ®  and ONICIT ®  (ALOXI ® ) in Russia and the CIS region for the prevention of chemotherapy-induced nausea and vomiting (CINV) to Berlin-Chemie AG (“Berlin-Chemie”), the German-based affiliate of the Menarini Group.

Company Video Menarini

MENARINI PILLS OF ART

Concession granted by Italian Ministry for Cultural Heritage and Activities Read more